GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » EV-to-Revenue

Amplia Therapeutics (ASX:ATX) EV-to-Revenue : (As of Jun. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Amplia Therapeutics's enterprise value is A$17.76 Mil. Amplia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was A$0.00 Mil. Therefore, Amplia Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Amplia Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 11 years, the highest EV-to-Revenue of Amplia Therapeutics was 9118.87. The lowest was -107.20. And the median was -7.30.

ASX:ATX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.83
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), Amplia Therapeutics's stock price is A$0.072. Amplia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was A$0.00. Therefore, Amplia Therapeutics's PS Ratio for today is .


Amplia Therapeutics EV-to-Revenue Historical Data

The historical data trend for Amplia Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics EV-to-Revenue Chart

Amplia Therapeutics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Amplia Therapeutics Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amplia Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Amplia Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amplia Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's EV-to-Revenue falls into.



Amplia Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Amplia Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=17.757/0
=

Amplia Therapeutics's current Enterprise Value is A$17.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics  (ASX:ATX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Amplia Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.072/0
=

Amplia Therapeutics's share price for today is A$0.072.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amplia Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Amplia Therapeutics (ASX:ATX) Business Description

Traded in Other Exchanges
Address
350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (ASX:ATX) Headlines

No Headlines